COVID-19: Could Aspirin Be of Any Help in the Early Stage?

Abstract

Here is discussed the current scientific background for starting antiaggregation with Aspirin in the very initial phase of COVID-19 infection for preventing thrombotic infarctions before irreversible damage occurs in the target organs.

Several authors are now describing the presence of endothelial cells into the bloodstream. This might indeed represent an epiphenomenon of the underlying mechanisms explaining the incidence of fatal systemic thrombotic complications.

Antiaggregation with ASA would potentially have a significant prophylactic role, ideally before than anticoagulation and/or intensive care be the only options left: therefore dedicated trials should urgently be addressed to confirm this hypothesis.

Note: Funding: None to declare

Declaration of Interest: None to declare

Keywords: COVID-19, Aspirin, antiaggregation, thrombosis, viral sepsis, endothelial cells